Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | DAO | P14920 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672795 | 1.00 | TAAR1 (0.39) | TAAR1DAOMAOAMAOBPTGER4 | |
| SCHEMBL5671815 | 0.79 | CYP3A4 (0.54) | CYP3A4 | |
| SCHEMBL7080429 | 0.79 | CYP3A4 (0.54) | CYP3A4 | |
| SCHEMBL5672405 | 0.77 | CA3 (0.40) | TAAR1DAOMAOBPTGER4PTGER3 | |
| SCHEMBL5672688 | 0.75 | DAO (0.41) | TAAR1DAOMAOAMAOBPTGER4 | |
| SCHEMBL5672870 | 0.73 | CYP3A4 (0.68) | TAAR1MAOACYP3A4 | |
| SCHEMBL5672862 | 0.73 | CYP3A4 (0.68) | TAAR1MAOACYP3A4 | |
| SCHEMBL29432878 | 0.73 | TAAR1 (0.50) | TAAR1MAOAMAOB | |
| SCHEMBL1499296 | 0.73 | TAAR1 (0.50) | TAAR1MAOAMAOB | |
| SCHEMBL11457781 | 0.72 | ALDH1A1 (0.48) | TAAR1DAOMAOAMAOBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236302-A1 | Synthetic derivatives | SYNTA PHARMACEUTICALS CORP. | 2003-12-25 | — | — | US | disclosed |
| WO-2003072103-A1 | SYNTHETIC DERIVATIVES | KAVA PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236302-A1 | Synthetic derivatives | CBR1, CBR3, REL | TAAR1 435/4885DAO 459/4885MAOA 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.